RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
EyeGate Pharmaceuticals - Stock

EyeGate Pharmaceuticals ROE 2024

EyeGate Pharmaceuticals ROE

0

Ticker

EYEG

ISIN

US30233M5031

WKN

A2PRBT

In 2024, EyeGate Pharmaceuticals's return on equity (ROE) was 0, a 0% increase from the 0 ROE in the previous year.

EyeGate Pharmaceuticals Aktienanalyse

What does EyeGate Pharmaceuticals do?

EyeGate Pharmaceuticals Inc. is a US pharmaceutical company specializing in the development of ophthalmology products. It was founded in 1998 and is headquartered in Waltham, Massachusetts. The company aims to meet the need for safe and effective therapies for the treatment of eye diseases. Its business model focuses on the development and commercialization of products that enable faster and more effective treatment of eye diseases. The company has two main divisions. The first division includes iontophoretic drug delivery technologies used for the treatment of eye diseases. Iontophoresis is a process in which electric currents are used to transport medications through the skin and into the eyes. EyeGate Pharmaceuticals has developed the EyeGate® II Delivery System technology, which allows for non-invasive, painless, and safe administration of medications into the eye. The EyeGate II Delivery System can be used for the treatment of inflammation, pain, and infections in the eye area. The second division is the development of drugs used for the treatment of eye diseases. EyeGate Pharmaceuticals has several clinical programs in development, including EGP-437, a steroid-free corticosteroid used for the treatment of inflammation of the anterior eye segment. EGP-437 is currently being tested in two clinical trials to demonstrate its efficacy and safety in the treatment of pain and inflammation in the eye. In addition, the company has developed the drug EGP-259 for the treatment of dry eye. EyeGate Pharmaceuticals has previously entered into several partnerships with other companies to further develop and commercialize its technology platform. In 2019, the company entered into a partnership with Valeant Pharmaceuticals International, Inc. to advance the marketing of EGP-437 in the United States. EyeGate Pharmaceuticals aims to continue growing and expanding its presence in the field of ophthalmology in the coming years. The company is working on the development of new products and technologies that enable it to respond to the changing needs and challenges in ophthalmology. Overall, EyeGate Pharmaceuticals is committed to developing and marketing innovative and effective technologies and drugs for the treatment of eye diseases. The company is well positioned to grow in a rapidly evolving market and make a significant contribution to improving the health and quality of life of millions of people worldwide. EyeGate Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding EyeGate Pharmaceuticals's Return on Equity (ROE)

EyeGate Pharmaceuticals's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing EyeGate Pharmaceuticals's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

EyeGate Pharmaceuticals's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in EyeGate Pharmaceuticals’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about EyeGate Pharmaceuticals Stock

What is the ROE (Return on Equity) of EyeGate Pharmaceuticals this year?

The ROE of EyeGate Pharmaceuticals this year is 0 undefined.

How has the Return on Equity (ROE) of EyeGate Pharmaceuticals developed compared to the previous year?

The ROE of EyeGate Pharmaceuticals has increased by 0% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of EyeGate Pharmaceuticals?

A high ROE indicates that EyeGate Pharmaceuticals generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of EyeGate Pharmaceuticals?

A low ROE can indicate that EyeGate Pharmaceuticals is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of EyeGate Pharmaceuticals affect the company?

A change in ROE (Return on Equity) of EyeGate Pharmaceuticals can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of EyeGate Pharmaceuticals?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of EyeGate Pharmaceuticals?

Some factors that can influence EyeGate Pharmaceuticals's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does EyeGate Pharmaceuticals pay?

Over the past 12 months, EyeGate Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, EyeGate Pharmaceuticals is expected to pay a dividend of 0.09 USD.

What is the dividend yield of EyeGate Pharmaceuticals?

The current dividend yield of EyeGate Pharmaceuticals is .

When does EyeGate Pharmaceuticals pay dividends?

EyeGate Pharmaceuticals pays a quarterly dividend. This is distributed in the months of April, May, June, July.

How secure is the dividend of EyeGate Pharmaceuticals?

EyeGate Pharmaceuticals paid dividends every year for the past 2 years.

What is the dividend of EyeGate Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0.09 USD are expected. This corresponds to a dividend yield of 0.26 %.

In which sector is EyeGate Pharmaceuticals located?

EyeGate Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von EyeGate Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of EyeGate Pharmaceuticals from 6/6/2024 amounting to 0.154 USD, you needed to have the stock in your portfolio before the ex-date on 6/3/2024.

When did EyeGate Pharmaceuticals pay the last dividend?

The last dividend was paid out on 6/6/2024.

What was the dividend of EyeGate Pharmaceuticals in the year 2023?

In the year 2023, EyeGate Pharmaceuticals distributed 0 USD as dividends.

In which currency does EyeGate Pharmaceuticals pay out the dividend?

The dividends of EyeGate Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von EyeGate Pharmaceuticals

Our stock analysis for EyeGate Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of EyeGate Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.